About inmed pharmaceuticals - INM
InMed Pharmaceuticals, Inc. is a pharmaceutical drug development company, which engages in developing small molecule drug candidates that are preferential signaling ligands of the endogenous CB1 and CB2 receptors as well as other receptor targets linked to human disease. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.
INM At a Glance
InMed Pharmaceuticals, Inc.
885 West Georgia Street
Vancouver, British Columbia V6C 3E8
| Phone | 1-604-669-7207 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -12,560,850.00 | |
| Sector | Health Technology | Employees | 6 | |
| Fiscal Year-end | 06 / 2027 | |||
| View SEC Filings |
INM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 7.699 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.459 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
INM Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,093,475.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
INM Liquidity
| Current Ratio | 1.369 |
| Quick Ratio | 1.369 |
| Cash Ratio | 1.143 |
INM Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -122.225 |
| Return on Equity | -156.768 |
| Return on Total Capital | -1,057.96 |
| Return on Invested Capital | -153.533 |
INM Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |